Purple Biotech Ltd. Sponsored ADR PPBT

Purple Biotech receives U.S. patent allowance that strengthens protection for its CAPTN-3 multispecific antibody. Patent allowance improves IP protection for core antibody technology.

Purple Biotech gains new U.S. patent allowance strengthening protection for its CAPTN-3 modular platform for next-generation multispecific antibodies. Patent bolsters IP protection for the company's core technology platform.

Purple Biotech Ltd. Sponsored ADR (PPBT) reported first quarter 2026 financial results and business highlights. Quarterly financial results and business updates moderately influence financial performance and investor sentiment.

Purple Biotech announced new data from its CAPTN-3 platform tri-specific IM1240. New data from CAPTN-3 tri-specific IM1240 advances Purple Biotech's oncology immunotherapy pipeline, potentially driving significant stock momentum and partnership interest.

Purple Biotech Ltd. establishes Scientific Advisory Board to support development of CAPTN-3 tri-specific antibody platform. Establishing a Scientific Advisory Board provides expert guidance for CAPTN-3 development, moderately enhancing product innovation and investor sentiment.

Purple Biotech announces AI collaboration with Converge Bio to accelerate development of its next-generation tri-specific antibody platform. AI collaboration accelerates next-generation tri-specific antibody platform, representing a major strategic move in biotech innovation.

Purple Biotech Ltd. Sponsored ADR (PPBT) has regained compliance with Nasdaq listing requirements after addressing prior deficiencies in minimum bid price and stockholders' equity standards. Regaining Nasdaq compliance averts delisting risk and restores full market visibility for PPBT.

Purple Biotech Ltd. announces CEO transition. CEO transition signals major leadership change with potential to reshape strategic direction and investor sentiment.

Purple Biotech Ltd. (PPBT) reported fourth quarter and full year 2025 financial results. Quarterly and annual financial results disclosure impacts financial performance and investor sentiment moderately.

Purple Biotech Ltd. has achieved a significant toxicology milestone for its CAPTN-3 platform tri-specific antibody, IM1240, demonstrating an expanded therapeutic window. This advancement is expected to enhance the drug's safety and efficacy profile, potentially leading to improved treatment options for patients. The company aims to leverage this progress to further develop its therapeutic offerings and strengthen its position in the biopharmaceutical market. The achievement of a toxicology milestone with an expanded therapeutic window is likely to significantly impact future product development and investor sentiment.

Purple Biotech Ltd. reported positive preclinical data showcasing multi-arm anti-tumor activity from two CAPTN-3 tri-specific antibodies at the ESMO Immuno-Oncology Congress 2025. The findings suggest potential advancements in cancer treatment, highlighting the company's innovative approach in immunotherapy. The positive preclinical data could significantly impact future product development and investor sentiment.

Purple Biotech Ltd. will present new preclinical data from its CAPTN-3 tri-specific antibody platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress. This presentation is expected to showcase advancements in the company's innovative therapeutic approaches in oncology, potentially attracting interest from investors and industry professionals. The presentation of new preclinical data could significantly influence investor sentiment and the company's strategic positioning in the oncology market.

Purple Biotech Ltd. reported its financial results for the third quarter of 2025, highlighting key metrics and providing updates on its business operations. The company continues to focus on its strategic initiatives and product development, aiming to enhance its market position and drive future growth. The financial results and business updates indicate moderate influences on the company's performance and market positioning.

Purple Biotech Ltd. has achieved a significant manufacturing milestone for IM1240, a tri-specific antibody developed from its CAPTN-3 platform. This advancement is expected to enhance the company's capabilities in producing innovative therapies, potentially positioning it favorably in the competitive biotech landscape. Achieving a manufacturing milestone for a new therapeutic candidate is likely to significantly impact future performance and investor sentiment.

Purple Biotech Ltd. has received an intention to grant a European patent for NT219, which covers its combinations with immunotherapies or MEK inhibitors aimed at overcoming tumor resistance. This development is expected to enhance the company's position in the oncology market by potentially improving treatment efficacy against resistant tumors. The patent could significantly impact future product offerings and competitive positioning in the oncology sector.

Purple Biotech Ltd. has successfully closed a public offering, raising up to $18 million, which includes $6 million upfront and the potential for an additional $12 million through the exercise of short-term warrants. This funding is expected to support the company's ongoing initiatives and development efforts. The public offering provides significant funding that may enhance financial performance and support product development.

Purple Biotech Ltd. announced new data supporting the design of its CAPTN-3 tri-specific antibody IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai. The data highlights the unique properties of IM1240, which may enhance its therapeutic potential in treating various cancers. This collaboration aims to advance the development of IM1240 and further validate its efficacy and safety profile. The new data on IM1240 could significantly impact the company's product pipeline and market positioning in the oncology sector.

Purple Biotech Ltd. has announced the pricing of a public offering of up to $18 million. The offering consists of 3.6 million American Depositary Shares (ADSs) at a price of $5 per ADS. The company intends to use the net proceeds for general corporate purposes, including funding clinical trials and working capital. The offering is expected to close on November 1, 2023, subject to customary closing conditions. The public offering may provide necessary funding for clinical trials, impacting financial performance and product development.

Purple Biotech Ltd. has expanded its CAPTN-3 portfolio with the introduction of IM1305, a novel tri-specific antibody that targets TROP2. This development aims to enhance the company's therapeutic offerings in oncology, potentially improving treatment options for patients with cancer. The new antibody is designed to engage multiple immune pathways, which may lead to more effective cancer treatments. The introduction of a novel tri-specific antibody targeting TROP2 represents a significant strategic move that could enhance Purple Biotech's competitive positioning in the oncology market.

Purple Biotech Ltd. reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to advance its clinical programs and maintain a strong cash position, which supports ongoing research and development efforts. Management expressed optimism about future prospects and strategic initiatives aimed at enhancing shareholder value. The financial results indicate moderate growth and ongoing clinical advancements that may influence investor sentiment and operational performance.

Purple Biotech Ltd. reported significant advancements in its clinical pipeline during the first half of 2025, as highlighted in a letter from CEO Gil Efron. Key achievements include promising Phase 2 results for CM24 in pancreatic cancer, showcasing strong objective response rates and progression-free survival data. The company also presented data on its CAPTN-3 tri-specific antibody platform and initiated a Phase 2 study for NT219 in combination with PD-1 or EGFR inhibitors. Upcoming catalysts include plans for a biomarker-driven Phase 2b study for CM24 and an IND application for CAPTN-3 in 2026. Financial management remains disciplined, with a runway extending into mid-2026, although additional funding will be necessary for future studies. Significant advancements in clinical trials and upcoming strategic initiatives are likely to impact the company's future performance.

Purple Biotech Ltd. presented new preclinical data on its CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Congress in Lisbon. The platform enables the creation of antibodies that activate both T cells and NK cells, targeting tumor immune evasion. The lead product, IM1240, showed significant anti-tumor activity in a triple negative breast cancer model, with conditional activation that minimizes systemic effects. The data highlight the platform's flexibility and potential for enhanced therapeutic efficacy against solid tumors. Additional tribodies demonstrated similar tumor regression, showcasing the platform's modular capabilities. The presentation of significant preclinical data on a novel therapeutic platform indicates a potential shift in the company's product development and market positioning.

Purple Biotech Ltd. has announced the initiation of a Phase 2 clinical study for NT219, a novel treatment for patients with head and neck cancer. This study aims to evaluate the safety and efficacy of NT219 in combination with other therapies, potentially offering new hope for patients with this challenging cancer type. The company is focused on advancing its pipeline and addressing unmet medical needs in oncology. Initiation of a Phase 2 study for a cancer treatment could significantly impact the company's future performance and investor sentiment.

Purple Biotech Ltd. announced a poster presentation at the EACR 2025 conference, showcasing its innovative CAPTN-3 tri-specific antibody platform. This platform aims to enhance cancer treatment by targeting multiple pathways simultaneously, potentially improving therapeutic efficacy. The presentation is expected to attract attention from researchers and investors in the oncology field, highlighting the company's commitment to advancing cancer therapies. The presentation of a novel tri-specific antibody platform could significantly influence investor sentiment and the company's future trajectory in cancer treatment.

Purple Biotech Ltd. reported its Q1 2025 financial results, highlighting significant progress in clinical trials for CM24 and NT219, with plans for a Phase 2b study of CM24 and a Phase 2 trial of NT219 in head and neck cancer. The company presented final Phase 2 data at the AACR Annual Meeting, showing promising efficacy in biomarker subgroups. R&D expenses decreased by 76.5% to $0.8 million, contributing to a reduced operating loss of $1.4 million. The company maintains a cash runway through mid-2026 and has strengthened its management team with a new CFO. Significant clinical trial advancements and reduced operating losses indicate a positive trajectory for future performance.

Purple Biotech Ltd. has appointed Shai Lankry as Chief Financial Officer. Lankry brings over 20 years of financial leadership in biotech and healthcare, with experience in U.S. IPOs and M&A transactions. CEO Gil Efron expressed confidence in Lankry's ability to guide the company through its late-stage trials and potential strategic partnerships. Lankry previously served as CFO at Gamida Cell Ltd. and held positions at West Pharmaceutical Services and MacroCure Ltd. Purple Biotech is focused on developing therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CM24, NT219, and CAPTN-3. The appointment of a seasoned CFO with extensive experience in biotech is likely to significantly impact the company's strategic direction and financial performance.

Purple Biotech Ltd. reported final data from its Phase 2 study of CM24 in pancreatic cancer patients, showing significant efficacy in biomarker-enriched subgroups. The study demonstrated up to a 90% reduction in risk of death and improved overall survival (OS) and progression-free survival (PFS) in patients with specific serum and tumor biomarkers. The combination of CM24, nivolumab, and chemotherapy was well tolerated and showed quantitative improvements across all efficacy parameters. The company plans to use these biomarkers for patient selection in the upcoming Phase 2b study, which may expand to other cancer indications. The study results indicate a significant advancement in treatment options for pancreatic cancer, potentially altering the company's market position and investor sentiment.

Purple Biotech Ltd. announced positive data for NT219 at the AACR 2025 Annual Meeting, highlighting its potential as a treatment for colorectal and head and neck cancers. NT219, a dual inhibitor of IRS1/2 and STAT3, showed significant upregulation of biomarkers associated with patient response, suggesting its efficacy in overcoming immune evasion and drug resistance. The company identified activated b-catenin and loss of APC as potential biomarkers for colorectal cancer treatment. These findings support ongoing Phase 2 studies combining NT219 with immunotherapies like pembrolizumab and cetuximab, aiming to expand patient populations benefiting from these therapies. Positive data from clinical studies and identification of biomarkers could significantly enhance NT219's market potential and investor sentiment.

Purple Biotech Ltd. announced the publication of research in the Neuro Oncology Journal, highlighting the potential of NT219 to suppress brain metastasis in colorectal cancer. The study suggests that NT219 may offer a novel therapeutic approach for patients with this condition, indicating promising implications for treatment strategies. The publication of significant research findings could lead to major advancements in treatment options and enhance the company's competitive positioning in the oncology market.

Purple Biotech Ltd. announced that CEO Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025. The panel, titled 'New Radiotherapy and Targeted Therapy Approaches,' is scheduled from 2:00 PM to 2:50 PM ET. The company is developing therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes CM24, NT219, and CAPTN-3. CM24 has shown promise in a Phase 2 study for pancreatic cancer, while NT219 is advancing into a Phase 2 study for head and neck cancer. CAPTN-3 is a preclinical platform of tri-specific antibodies targeting tumors. The company's headquarters are in Rehovot, Israel. Participation in a significant oncology conference may enhance visibility and interest in the company's innovative therapies.